EQS-News: Marinomed Biotech AG / Key word(s): Market Launch
Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria
10.04.2025 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria
• Carragelose eye drops for the treatment of dry eyes launched under the trade name “Coldamaris protect” in Austria
• Eye drops complement existing Carragelose product portfolio now owned by Unither Pharmaceuticals and are important for reaching contractually agreed earn-out
milestones
• Furthermore, the decongestant Carragelose-containing nasal spray has received declaration of conformity under the new medical device regulation (MDR)
Korneuburg, Austria, 10. April 2025 – Marinomed Biotech AG (VSE:MARI) announces that the Austrian distribution partner Sigmapharm has launched the moisturizing eye
drops under the trade name “Coldamaris protect” further to a license deal signed in 2023. The eye drops complement the existing Carragelose over-the-counter (OTC)
product portfolio consisting of nasal sprays and throat products for the prophylaxis and treatment of viral respiratory diseases. In a clinical study conducted in
Spain in 2024, the eye drops improved dry-eye related symptoms by remarkable 54% while being well tolerated by patients with mild to moderate dry eye syndrome.
In 2024, the Carragelose business has been sold to the French Company Unither Pharmaceuticals. Marinomed now supports Unither in transferring the business and
successfully continuing the growth of the portfolio. The launch of the eye drops is an important milestone for reaching contractually agreed milestones regarding
the earn-out components of the contract.
Furthermore, Marinomed has made considerable progress in transferring the Carragelose product portfolio to the new medical device regulation (MDR). Next to other
Carragelose nasal sprays, now also the decongestant nasal spray, containing a combination of Carragelose and sorbitol, has received the declaration of conformity
und the MDR. The MDR, which replaces the previously valid medical device directive (MDD), sets new EU-wide standards regarding the requirements for safety,
performance, quality of clinical data and overall technical documentation for medical devices.
Eva Prieschl-Grassauer, CSO of Marinomed, comments: “Together with an outstanding safety profile and other key benefits, Carragelose is an ideal compound for
providing relief for dry eyes. Introducing the Carragelose eye drops to the product range is a logical addition and complements the existing product portfolio.
This launch as well as the ongoing transfer of the products to the new MDR supports the positive development of the Carragelose portfolio, which also influences
the earn-out components of the deal between Unither and Marinomed.”
About Carragelose®
Carragelose® is a sulfated polymer from red seaweed and a unique, broadly active virus- and allergen-blocking compound. It is known as a gentle, effective, and
safe prevention and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a protective
layer on the mucosa that prevents viruses from infecting cells. Laboratory and clinical data have demonstrated that Carragelose® can also inhibit the spreading of
SARS-CoV-2.(1)^(1)^,(2)(2) Carragelose® products have been outlicensed for marketing in Europe, North America, Australia, and parts of Asia and Latin America. The
portfolio of Carragelose®-containing nasal sprays and oral products can be accessed at (3)https://www.carragelose.com/en/portfolio/launched-products, scientific
publications on Carragelose® at (4)https://www.carragelose.com/en/publications. In February 2025, the whole Carragelose® portfolio has been transferred to the
French company Unither Pharmaceuticals.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products
based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new
therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: (5)https://www.marinomed.com.
For further inquiries contact:
PR: Lucia Ziegler IR: Tobias Meister
Marinomed Biotech AG Meister Consulting GmbH
T: +43 2262 90300 158 T: +43 2262 90300
E-Mail: (6)pr@marinomed.com E-Mail: (7)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG
about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to
differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of
Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”,
“project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update,
review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed
and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
(8)^(1) (9)https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM
(10)^(2)
(11)https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1
═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
10.04.2025 CET/CEST This Corporate News was distributed by EQS Group. www.eqs.com
═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2114620
End of News EQS News Service
2114620 10.04.2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2114620&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf
References
Visible links
1. file:///appl/crsred1/tmp/HTML-FormatExternal-YHVRrO.html#_edn1
2. file:///appl/crsred1/tmp/HTML-FormatExternal-YHVRrO.html#_edn2
3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2a3dda556ab52fe6b2a10b732e7834&application_id=2114620&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=43c84c05c837223116d24f9889459559&application_id=2114620&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2114620&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
6. mailto:pr@marinomed.com
7. mailto:ir@marinomed.com
8. file:///appl/crsred1/tmp/HTML-FormatExternal-YHVRrO.html#_ednref1
9. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=33ccd3741e11d696674979569046f638&application_id=2114620&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
10. file:///appl/crsred1/tmp/HTML-FormatExternal-YHVRrO.html#_ednref2
11. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=21dfc7afdd676fd13f5e421e04701661&application_id=2114620&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |